Phenotypic study of humanized mice carrying the PAH deep intronic variant c.1199+502A>T

The c.1199 + 502 A > T variant of the phenylalanine hydroxylase (PAH) gene, which is the most frequently reported deep intronic variant involved in phenylketonuria (PKU), is mainly observed in patients with classical or mild PKU. Prior to this study, no mouse models of PKU featuring deep intronic variants of PAH had been reported. To phenotypically simulate the pathogenicity of this variant, we used CRISPR/Cas9 genome editing technology and homologous recombination to generate homozygous PKU model mice with a partially humanized Pah gene incorporating human PAH exons 11–12 carrying c.1199 + 502 A > T or wild-type (c.1199 + 502WT) control sequences. Humanized homozygous Pah c.1199 + 502 A > T mice exhibited a classical PKU phenotype, including a higher serum phenylalanine concentration, yellowing of the fur, and other traits. The homozygous mutant group had poorer spatial learning and spatial memory compared with the wild-type group. This construction of the first humanized mice carrying a deep intronic variant of PAH provides a new animal model for the pathogenesis and treatment of PKU, and may serve as a reference for future research on the pathogenicity of deep intronic variation.

• Publication year

  2025

• Venue

  Orphanet Journal of Rare Diseases

• Publication date

  2025-05-26

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1186/s13023-025-03800-6PMID 40420248PMCID 12107979
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Characterizing the mechanism of action for mRNA therapeutics for the treatment of propionic acidemia, methylmalonic acidemia, and phenylketonuria

  2024cited by this paper
• Engineered Probiotics for the Management of Congenital Metabolic Diseases: A Systematic Review

  2024cited by this paper
• Rapid and definitive treatment of phenylketonuria in variant-humanized mice with corrective editing

  2023cited by this paper
• Identification of deep intronic variants of PAH in phenylketonuria using full-length gene sequencing

  2023influential reference
• The spectrum of phenylalanine hydroxylase variants and genotype–phenotype correlation in phenylketonuria patients in Gansu, China

  2023cited by this paper
• Clinical, genetic, and experimental research of hyperphenylalaninemia

  2023cited by this paper
• PAH deficient pathology in humanized c.1066-11G>A phenylketonuria mice

  2023influential reference
• Identification of phenylketonuria patient genotypes using single-gene full-length sequencing

  2022influential reference
• Phenylketonuria

  2021cited by this paper
• Identification of novel deep intronic PAH gene variants in patients diagnosed with phenylketonuria

  2021cited by this paper
• A noncoding RNA modulator potentiates phenylalanine metabolism in mice

  2021cited by this paper
• The Pah-R261Q mouse reveals oxidative stress associated with amyloid-like hepatic aggregation of mutant phenylalanine hydroxylase

  2021influential reference
• The Genetic Landscape and Epidemiology of Phenylketonuria.

  2020cited by this paper
• Anthropometry and bone mineral density in treated and untreated hyperphenylalaninemia

  2020cited by this paper
• 5-year retrospective analysis of patients with phenylketonuria (PKU) and hyperphenylalaninemia treated at two specialized clinics.

  2019cited by this paper
• Phenylketonuria incidence in China between 2013 and 2017 based on data from the Chinese newborn screening information system: a descriptive study

  2019cited by this paper
• Long-Term Growth in Phenylketonuria: A Systematic Review and Meta-Analysis

  2019influential reference
• Relationship between genotype, phenylalanine hydroxylase expression and in vitro activity and metabolic phenotype in phenylketonuria.

  2018cited by this paper
• Treatment of a metabolic liver disease by in vivo genome base editing in adult mice

  2018cited by this paper
• Growth and Final Height Among Children With Phenylketonuria

  2017cited by this paper
• Early-onset behavioral and neurochemical deficits in the genetic mouse model of phenylketonuria

  2017cited by this paper
• Mouse models of human disease

  2016cited by this paper
• Mouse models of human disease evolutionary perspective

  2016cited by this paper
• Mapping the functional landscape of frequent phenylalanine hydroxylase (PAH) genotypes promotes personalised medicine in phenylketonuria

  2015cited by this paper
• Linking genotypes database with locus-specific database and genotype–phenotype correlation in phenylketonuria

  2014cited by this paper
• Phenylalanine hydroxylase deficiency: diagnosis and management guideline

  2013cited by this paper
• Phenylketonuria.

  2010cited by this paper
• Preclinical evaluation of multiple species of PEGylated recombinant phenylalanine ammonia lyase for the treatment of phenylketonuria

  2008cited by this paper
• Efficacy of sapropterin dihydrochloride (tetrahydrobiopterin, 6R-BH4) for reduction of phenylalanine concentration in patients with phenylketonuria: a phase III randomised placebo-controlled study.

  2007cited by this paper
• Characterization of the mouse phenylalanine hydroxylase mutation Pah(enu3).

  2001cited by this paper
• A heteroallelic mutant mouse model: A new orthologue for human hyperphenylalaninemia.

  2000cited by this paper
• Characterization of mutations at the mouse phenylalanine hydroxylase locus.

  1997cited by this paper
• Impaired prenatal and postnatal growth in Dutch patients with phenylketonuria. The National PKU Steering Committee.

  1994cited by this paper
• Birthweights in children with phenylketonuria and in their siblings.

  1972cited by this paper
• Phenylketonuria

  1961cited by this paper

• No citing papers are available for this paper.